Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MIRA Pharmaceuticals, Inc. Common Stock (MIRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MIRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.38
1 Year Target Price $10.38
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.85% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 34.32M USD | Price to earnings Ratio - | 1Y Target Price 10.38 |
Price to earnings Ratio - | 1Y Target Price 10.38 | ||
Volume (30-day avg) 1 | Beta 1.72 | 52 Weeks Range 0.73 - 2.56 | Updated Date 10/17/2025 |
52 Weeks Range 0.73 - 2.56 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.47 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -253.31% | Return on Equity (TTM) -556.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22025460 | Price to Sales(TTM) - |
Enterprise Value 22025460 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.45 | Shares Outstanding 19069315 | Shares Floating 12137428 |
Shares Outstanding 19069315 | Shares Floating 12137428 | ||
Percent Insiders 36.57 | Percent Institutions 5.06 |
Upturn AI SWOT
MIRA Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
MIRA Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on the development of novel therapies to address unmet medical needs in the areas of neurology, psychiatry and pain management. It was founded to advance new treatments using synthetic cannabinoid analogs.
Core Business Areas
- Neurology & Psychiatry: Development of novel therapies for neurological and psychiatric disorders, targeting conditions such as anxiety, PTSD, and epilepsy.
- Pain Management: Development of non-opioid pain management solutions using synthetic cannabinoid analogs.
Leadership and Structure
Erez Aminayov serves as the Chairman and Chief Executive Officer. The company has a board of directors and a scientific advisory board guiding its research and development efforts.
Top Products and Market Share
Key Offerings
- MIRA1a: MIRA1a is the lead product candidate, a synthetic cannabinoid analog being developed for the treatment of anxiety and neurological diseases. It is currently in pre-clinical development. Market share data is not yet available as it has not been commercialized. Competitors in the anxiety treatment market include pharmaceutical companies such as Pfizer and Eli Lilly, which offer medications like SSRIs and benzodiazepines.
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing growth in areas of neurological disorders and pain management due to increasing prevalence of these conditions and a demand for safer, more effective treatments.
Positioning
MIRA Pharmaceuticals is positioned as an early-stage company focused on developing novel cannabinoid-based therapies. Its competitive advantage lies in its proprietary compounds and focus on unmet needs in neurology and pain management.
Total Addressable Market (TAM)
The global anxiety disorders market is estimated to be worth tens of billions of dollars. MIRA Pharmaceuticals, Inc. Common Stock is positioned to penetrate this large TAM market by providing alternative non-addictive medication.
Upturn SWOT Analysis
Strengths
- Proprietary compounds
- Focus on unmet medical needs
- Experienced leadership team
- Novel approach to cannabinoid therapeutics
Weaknesses
- Pre-clinical stage with no approved products
- Limited financial resources
- High regulatory risk
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline
- Positive clinical trial results
- Growing market for alternative pain management solutions
Threats
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Failure to secure funding
- Unfavorable clinical trial outcomes
Competitors and Market Share
Key Competitors
- LLY
- PFE
- ABBV
- GWPH
Competitive Landscape
MIRA Pharmaceuticals faces intense competition from established pharmaceutical companies with significantly greater resources. Its success depends on differentiating its products through improved efficacy or safety profiles.
Growth Trajectory and Initiatives
Historical Growth: Not applicable due to pre-revenue stage.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its product candidates. Analyst estimates are not available.
Recent Initiatives: Recent initiatives include advancing MIRA1a through pre-clinical development and exploring potential partnerships.
Summary
MIRA Pharmaceuticals is a high-risk, high-reward pre-clinical company with a focus on novel cannabinoid therapies. Its success hinges on the success of its lead compound, MIRA1a, in clinical trials. The company faces significant competition and regulatory hurdles, but positive clinical data could lead to substantial growth. MIRA needs to secure adequate funding to support its development programs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MIRA Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2023-08-03 | CEO & Chairman Mr. Erez Aminov | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees - | Website https://mirapharmaceuticals.com |
Full time employees - | Website https://mirapharmaceuticals.com | ||
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.